FDA Warning Letter

Regulatory Event

Woodbine Products Company Inc., a Medina, Ohio manufacturer of over-the-counter topical and ethanol-based drug products, received FDA Warning Letter 320-26-107 on July 27, 2026, following a February 9–13, 2026 inspection of its 915 W. Smith Road facility. The lead finding: Woodbine did not perform identity testing on incoming shipments of glycerin, propylene glycol, or ethanol before using them to manufacture finished OTC drug products — and it used nonpharmaceutical-grade propylene glycol in that manufacturing, cited under 21 CFR 211.84(d)(1).

The specific components at issue are not incidental. Glycerin and propylene glycol are the two ingredients most associated with a well-documented category of mass poisoning events: contamination with diethylene glycol (DEG) or ethylene glycol (EG), both of which are toxic industrial solvents sometimes substituted or blended into glycerin supply chains because they are cheaper and difficult to distinguish from the genuine ingredient without a specific identification test. In 2006, DEG-contaminated glycerin that entered a supply chain through China was used to manufacture cough syrup in Panama, killing more than 100 people. In 2022, DEG- and EG-contaminated cough syrups manufactured by Maiden Pharmaceuticals in India were linked to acute kidney injury deaths among children in The Gambia; a comparable event tied to Marion Biotech’s cough syrup in Uzbekistan followed in late 2022 and early 2023. FDA’s own guidance, cited directly in this Warning Letter, requires a United States Pharmacopeia (USP) identification test capable of detecting these hazardous impurities on each shipment of each lot of glycerin and comparable high-risk components — precisely the test Woodbine did not perform. Separately, Woodbine also did not test incoming ethanol for methanol contamination, another well-established source of lethal poisoning, and could not demonstrate that its ethanol met USP monograph specifications for impurities including acetaldehyde and benzene.

What the Record Documents

Woodbine’s March 2026 response to the Form FDA 483 stated that it had tested retain samples from nine propylene glycol lots for DEG and EG contamination, and acknowledged that retain samples from three additional lots were no longer available for testing at all — meaning any DEG or EG contamination in those three lots is now permanently unverifiable from the affected batch’s own supply chain. The response committed to performing full USP identity and impurity testing going forward but did not include procedural controls demonstrating how future identity testing would actually be executed, did not investigate why nonpharmaceutical-grade propylene glycol had been accepted into a drug manufacturing process in the first place, and did not evaluate the impact of previously distributed product manufactured with untested components. FDA found the response inadequate on all three grounds. The underlying regulatory principle is straightforward under 21 CFR 211.84: without identity testing, a firm has no scientific evidence that an incoming component actually conforms to its specification before it enters a drug product, regardless of what the supplier’s certificate of analysis claims.

The letter’s second citation, under 21 CFR 211.100(a), extends the finding from raw materials to the manufacturing process itself. Woodbine had not performed process performance qualification studies for its drug products and had no ongoing program for monitoring intra-batch or inter-batch process variation — meaning the firm had no data-driven basis for asserting that its manufacturing process reliably produced product meeting specification, independent of the component testing gap. Cleaning validation for non-dedicated, shared equipment was similarly absent. FDA’s inspection also flagged that an unspecified water or process fluid system used in manufacturing had not been demonstrated suitable for its intended use, with no routine monitoring of microbial counts or organism identity to confirm the system remained in a state of control — a gap directly relevant given that several Woodbine products are aqueous or hydroalcoholic formulations where the process water itself is a component subject to the same identity-and-quality logic as glycerin or ethanol.

Technical and Quality Context

The third citation, under 21 CFR 211.22, is the one that explains why FDA characterized these as repeat violations and recommended a mandatory consultant engagement under 21 CFR 211.34 rather than a standard corrective-action review. Woodbine’s quality unit had not established adequate written responsibilities and procedures under 211.22(d), had not established scientifically sound laboratory controls under 211.160(b), had not performed the laboratory determination of conformance to specification required before batch release under 211.165(a), had no adequate stability testing program under 211.166(a), and lacked adequate batch production and control records under 211.188. Five distinct citations against a single quality unit, spanning procedure, laboratory control, release testing, stability, and batch documentation, is not a narrow gap. It is evidence that the quality unit was not functioning as the Current Good Manufacturing Practice (CGMP) control point at all, and FDA’s letter states this plainly: the firm does not operate an effective quality system in accordance with CGMP.

The letter closes with a reminder that is easy to overlook amid the CGMP citations: some of Woodbine’s products may also be regulated as cosmetics under section 201(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and FDA flagged that any cosmetic products the firm manufactures must independently comply with the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which introduced facility registration, product listing, and safety substantiation requirements that did not previously apply to cosmetic manufacturers. For a firm manufacturing topical and hydroalcoholic products, the drug/cosmetic boundary is not always self-evident at the formulation level, and a company correcting its drug-side quality system still needs a parallel check that its cosmetic-classified products, if any, meet MoCRA’s separate obligations — a compliance gap that a CGMP remediation plan alone will not close.

Decision Relevance

For OTC manufacturers reading this letter, the practical lesson is that raw material identity testing is not a formality that a supplier’s certificate of analysis can substitute for, particularly for the small list of components — glycerin, propylene glycol, sorbitol solution, maltitol solution, and comparable polyols, plus ethanol and isopropyl alcohol — that FDA has specifically flagged as high-risk for DEG, EG, or methanol contamination following the 2022–2023 poisoning events. A supplier qualification program that accepts a certificate of analysis in lieu of incoming identity testing needs a documented, statistically valid basis for that reliance, established through initial and periodic supplier verification, not an assumption of trust. Firms that discover, as Woodbine did, that retain samples from some lots are simply unavailable need to treat that gap itself as a finding requiring a documented risk assessment of the distributed batches involved, not a footnote in a response letter. This is where XGene Consulting’s raw material qualification and analytical method development practice adds direct value: building the identity and impurity testing program, method validation aligned to International Council for Harmonisation (ICH) Q2(R2), and supplier qualification framework that closes this exposure before an inspector finds it, and designing the process and cleaning validation lifecycle that a quality unit needs to actually exercise its 211.22 authority rather than exist on paper. If your firm manufactures OTC products containing glycerin, propylene glycol, or alcohol and cannot produce lot-specific USP identity test results on demand, that is worth resolving now. Reach out to discuss a confidential raw material and quality system gap assessment.